EMP
Pre-clinical- Indications
- Type 1 diabetes, Type 2 diabetes
Company intelligence / Profile preview
Betalin Therapeutics has developed a proprietary engineered micro-pancreas platform that combines a three-dimensional scaffold with human pancreatic islets and mesenchymal stem cells. In preclinical animal models, the implant demonstrated prolonged viability of transplanted cells and sustained insulin production. The company has completed preclinical studies and received positive feedback from the FDA on its pre-investigational new drug application. Clinical trial preparations are underway at leading centers worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Betalin Therapeutics.